Safety and efficacy of hepatic artery transarterial chemoembolization combined with apatinib in the treatment of primary liver cancer
AIM To analyze the safety and efficacy of hepatic artery transarterial chemoembolization(TACE)combined with apatinib in treating primary liver cancer.METHODS A total of 72 patients with primary liver cancer admitted from June 2021 to June 2022 were collected.The study subjects were randomly divided into the TACE group including 36 cases treated with the TACE alone and the combination group including 36 cases treated with the TACE combined with apatinib.The clinical efficacy of 2 groups was compared.RESULTS After treatment,the levels of total bilirubin(TBil),alanine aminotransferase(ALT),aspartate aminotransferase(AST),CD8+and the incidence of adverse reactions in combination group were lower than those in the TACE group.The levels of CD4+and CD4+/CD8+in combination group were higher than those in the TACE group.The effective rate of treatment in combination group was higher than that in the TACE group,and the differences were statistically significant(P<0.05).CONCLUSION The TACE combined with apatinib treatment can significantly improve liver function and immune function of patients with high effectiveness and no increase in the incidence of adverse drug reactions,which is valuable for clinical promotion.
hepatic artery transarterial chemoembolizationapatinibprimary liver cancerliver functionimmune functionadverse drug reaction